GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia
GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta™ (eltrombopag).
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Anemia | Aplastic Anemia | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals